Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System
Bausch Health and its aesthetic business Solta Medical have received Health Canada clearance for their Thermage FLX system, an advanced non-invasive radiofrequency skin tightening technology.
The fourth-generation Thermage FLX system offers several key improvements:
- 25% faster treatments with a larger 4.0 cm² treatment tip
- Enhanced patient comfort through integrated vibration and cooling
- Smart AccuREP technology that adjusts RF energy based on skin impedance
- Ergonomic handpiece design for improved provider workflow
- Versatile applications for face, eyes, and body treatments
This approval marks a significant milestone for Bausch Health's aesthetic business growth in Canada, bringing the same advanced technology already used in leading aesthetic clinics worldwide to Canadian providers and patients. The system builds on Thermage's 20-year legacy of trusted non-invasive skin tightening solutions.
Bausch Health e la sua divisione estetica Solta Medical hanno ottenuto l'autorizzazione da Health Canada per il loro sistema Thermage FLX, una tecnologia avanzata di radiofrequenza non invasiva per il rassodamento della pelle.
Il sistema Thermage FLX di quarta generazione presenta diversi miglioramenti chiave:
- Trattamenti più veloci del 25% grazie a una punta di trattamento più ampia da 4,0 cm²
- Maggiore comfort per il paziente grazie a vibrazioni integrate e raffreddamento
- Tecnologia Smart AccuREP che regola l'energia RF in base all'impedenza della pelle
- Design ergonomico del manipolo per un flusso di lavoro ottimizzato per l'operatore
- Applicazioni versatili per trattamenti di viso, occhi e corpo
Questa approvazione rappresenta una tappa importante per la crescita del business estetico di Bausch Health in Canada, offrendo la stessa tecnologia avanzata già utilizzata nelle principali cliniche estetiche a livello mondiale ai fornitori e ai pazienti canadesi. Il sistema si basa sulla consolidata esperienza di Thermage, con una storia di 20 anni di soluzioni affidabili per il rassodamento non invasivo della pelle.
Bausch Health y su división estética Solta Medical han recibido la aprobación de Health Canada para su sistema Thermage FLX, una avanzada tecnología de radiofrecuencia no invasiva para el tensado de la piel.
El sistema Thermage FLX de cuarta generación ofrece varias mejoras clave:
- Tratamientos un 25% más rápidos con una punta de tratamiento más grande de 4,0 cm²
- Mayor comodidad para el paciente gracias a la vibración integrada y enfriamiento
- Tecnología Smart AccuREP que ajusta la energía de RF según la impedancia de la piel
- Diseño ergonómico del aplicador para mejorar el flujo de trabajo del proveedor
- Aplicaciones versátiles para tratamientos en rostro, ojos y cuerpo
Esta aprobación representa un hito importante para el crecimiento del negocio estético de Bausch Health en Canadá, llevando la misma tecnología avanzada ya utilizada en clínicas estéticas líderes a nivel mundial a proveedores y pacientes canadienses. El sistema se basa en los 20 años de legado de Thermage en soluciones confiables de tensado no invasivo de la piel.
Bausch Health와 그 미용 사업부 Solta Medical가 캐나다 보건부(Health Canada)로부터 Thermage FLX 시스템에 대한 승인을 받았습니다. 이 시스템은 진보된 비침습적 고주파 피부 탄력 기술입니다.
4세대 Thermage FLX 시스템은 다음과 같은 주요 개선점을 제공합니다:
- 4.0 cm²의 더 큰 치료 팁으로 치료 속도 25% 향상
- 통합 진동 및 냉각 기능으로 환자 편안함 증대
- 피부 임피던스에 따라 RF 에너지를 조절하는 스마트 AccuREP 기술
- 작업자의 작업 흐름 향상을 위한 인체공학적 핸드피스 디자인
- 얼굴, 눈, 몸 등 다양한 부위에 적용 가능
이번 승인은 캐나다 내 Bausch Health 미용 사업 성장에 중요한 이정표가 되며, 전 세계 주요 미용 클리닉에서 이미 사용 중인 동일한 첨단 기술을 캐나다의 의료 제공자와 환자에게 제공하게 됩니다. 이 시스템은 Thermage가 20년간 쌓아온 신뢰받는 비침습적 피부 탄력 솔루션의 전통을 이어갑니다.
Bausch Health et sa division esthétique Solta Medical ont obtenu l'autorisation de Santé Canada pour leur système Thermage FLX, une technologie avancée de radiofréquence non invasive pour le raffermissement de la peau.
Le système Thermage FLX de quatrième génération propose plusieurs améliorations clés :
- Des traitements 25 % plus rapides grâce à une embout de traitement plus large de 4,0 cm²
- Un confort patient amélioré grâce à des vibrations intégrées et un système de refroidissement
- La technologie Smart AccuREP qui ajuste l'énergie RF en fonction de l'impédance de la peau
- Un design ergonomique du dispositif pour faciliter le travail du praticien
- Des applications polyvalentes pour les traitements du visage, des yeux et du corps
Cette approbation constitue une étape importante dans le développement de l'activité esthétique de Bausch Health au Canada, en offrant la même technologie avancée déjà utilisée dans les cliniques esthétiques de premier plan dans le monde aux professionnels et patients canadiens. Le système s'appuie sur les 20 ans d'expérience de Thermage en solutions fiables de raffermissement cutané non invasif.
Bausch Health und seine ästhetische Sparte Solta Medical haben die Zulassung von Health Canada für ihr Thermage FLX System erhalten, eine fortschrittliche nicht-invasive Radiofrequenz-Technologie zur Hautstraffung.
Das Thermage FLX System der vierten Generation bietet mehrere wesentliche Verbesserungen:
- 25 % schnellere Behandlungen dank größerer Behandlungsspitze von 4,0 cm²
- Verbesserter Patientenkomfort durch integrierte Vibration und Kühlung
- Smart AccuREP-Technologie, die die RF-Energie basierend auf dem Hautwiderstand anpasst
- Ergonomisches Handstückdesign für einen verbesserten Arbeitsablauf des Anwenders
- Vielseitige Anwendungen für Gesichts-, Augen- und Körperbehandlungen
Diese Zulassung markiert einen bedeutenden Meilenstein für das Wachstum des ästhetischen Geschäfts von Bausch Health in Kanada und bringt dieselbe fortschrittliche Technologie, die bereits in führenden ästhetischen Kliniken weltweit eingesetzt wird, zu kanadischen Anbietern und Patienten. Das System baut auf der 20-jährigen Erfolgsgeschichte von Thermage mit bewährten nicht-invasiven Hautstraffungslösungen auf.
- Health Canada approval for Thermage FLX system expands market reach
- 25% faster treatment delivery compared to previous generations
- Product represents fourth generation of technology, showing continued R&D progress
- Builds on existing 20-year market presence and established provider trust
- None.
Insights
Health Canada's approval of Thermage FLX advances Bausch's aesthetic portfolio with upgraded technology poised to drive growth.
The Health Canada clearance of Bausch Health's Thermage FLX system represents a significant milestone for the company's aesthetic business division. As the fourth generation of Solta Medical's monopolar radiofrequency technology, this approval brings a globally established platform to the Canadian market where providers have reportedly been awaiting its arrival.
The technical advancements are substantial and market-relevant. The new Total Tip 4.0 delivers treatments 25% faster than previous generations—a meaningful efficiency improvement for aesthetic practices. The AccuREP™ technology, which dynamically adjusts RF energy based on individual skin impedance, represents a personalization feature that addresses varying patient needs.
From a competitive standpoint, the ergonomic improvements and integrated comfort features (vibration and cooling) directly address historical pain points with RF treatments. These enhancements target both practitioner efficiency and patient experience—two critical factors driving adoption in the premium aesthetic device market.
The versatility of applications (face, eyes, and body treatments) maintains the system's broad clinical utility while the redesigned handpiece improves provider workflow. Particularly noteworthy is the CEO's explicit statement connecting this approval to "continued growth" of their aesthetic business, signaling its strategic importance within Bausch Health's diversified portfolio. This approval extends Thermage's 20-year market presence into a new generation of technology for Canadian aesthetic providers.
Thermage FLX clearance strengthens Bausch's aesthetic segment in Canada, expanding their high-margin medical device portfolio with improved technology.
This regulatory clearance represents a strategic win for Bausch Health in the premium aesthetic device segment. The approval brings their flagship non-invasive skin tightening technology to the Canadian market, positioning the company to capitalize on what appears to be established demand, as evidenced by the mention that Canadian providers have "eagerly awaited" this system.
From a business perspective, the Thermage franchise serves as an important component of Bausch's diversification strategy. The aesthetic segment offers several advantages: cash-pay procedures that aren't subject to insurance reimbursement pressures, high margins typical of premium medical devices, and recurring revenue from treatment tips and accessories.
The 25% faster treatment capability directly addresses clinic economics by potentially increasing patient throughput—a key consideration for practices evaluating ROI on capital equipment purchases. Additionally, the improved ergonomics and enhanced patient comfort features address practical adoption barriers that influence purchasing decisions.
CEO Thomas Appio's characterization of this approval as "important for the continued growth of our aesthetic business" signals the strategic significance of the Thermage product line within Bausch's portfolio. While the press release doesn't quantify expected revenue impact, the introduction of next-generation technology into a market with pent-up demand typically creates an opportunity for both new system placements and upgrades from existing users of older technology.
A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market
LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, announced today that Health Canada has granted medical device license clearance for Thermage® FLX, the latest generation of the globally-recognized Thermage® system for non-invasive skin tightening and contouring.
"The clearance of Thermage FLX in Canada is a positive development for our company and important for the continued growth of our aesthetic business", said Thomas J. Appio, Chief Executive Officer, Bausch Health. "As the pioneer in non-invasive skin tightening, Thermage has earned trust worldwide, and we're thrilled to bring the latest generation of this globally recognized technology to Canadian providers and patients who have been waiting for it."
Thermage FLX represents the fourth generation of innovation in monopolar radiofrequency (RF) technology from Solta Medical. With a long legacy of trust among providers and patients, the Thermage platform is a globally established system trusted by providers for more than 20 years. In Canada, providers have eagerly awaited the next evolution of this system, and they will now gain access to the same smart technology already in use by leading aesthetic clinics around the world.
"Thermage FLX was designed with both providers and patients in mind. With enhanced ergonomics, smart impedance feedback, and improved comfort, it delivers the personalized treatment experience patients are seeking and the reliable results providers expect from Thermage," said Jiny Kim, Senior Vice President, Solta Medical, Bausch Health.
Key Features of Thermage FLX:
Larger Treatment Tip: The 4.0 cm² Total Tip 4.0 delivers
25% faster treatments compared to previous generations, increasing efficiency while maintaining consistent results.Enhanced Patient Comfort: Integrated vibration and cooling improve patient experience during treatment.
Smart Impedance Technology: AccuREP™ technology reads skin impedance and adjusts RF energy output with each pulse, tailoring treatment to each patient's unique skin needs.
Ergonomic Design: A redesigned handpiece improves ease of use for providers, supporting precise delivery and a more comfortable workflow.
Versatile Applications: For the non-invasive treatments of wrinkles and rhytids on the face, eyes, and body-including areas with thinner or more delicate skin.
With the approval of Thermage FLX, Solta Medical continues to build on its legacy of science-backed, non-invasive technologies-and support providers with smart systems that deliver consistent results across a range of patient needs.
To learn more about Thermage and the full Solta Medical portfolio, visit ca.solta.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our aesthetic business, Solta Medical, is a global leader in medical aesthetics with a portfolio of well-known, science-backed technologies. Thermage FLX has been cleared for use by Health Canada. Solta Medical has device clearances in 80 countries globally. For information about your specific region, visit www.bauschhealth.com and www.solta.com. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Investor Contact: | Media Contact: |
Garen Sarafian | Katie Savastano |
(877) 281-6642 (toll free) | (908) 569-3692 |
SOURCE: Bausch Health Companies Inc.
View the original press release on ACCESS Newswire
FAQ
What are the key features of Bausch Health's new Thermage FLX system approved in Canada?
How does the Thermage FLX approval impact Bausch Health (BHC) in Canada?
What improvements does Thermage FLX offer over previous generations?
Where can Thermage FLX be used on the body?
How long has Thermage technology been trusted by providers?
